Johnson & Johnson price to book ratio JNJ

Market value divided by the book value of the company's net assets, since 2009.

Today, Oct 23, 2026: 7.5×
10-year median: 5.8×
Against its 10-year history: 98th; percentile: 0 is its lowest day, 100 its highest
10-year range: 4.2× to 7.8×
Peer median: 12.5×

Johnson & Johnson's price to book ratio is 7.5× as of Oct 23, 2026.

That is above its ten-year median of 5.8×, higher than on 98% of days in the last ten years.

Over that time it ranged from 4.2× in Dec 2016 to 7.8× in Sep 2026.

The median for 7 large drugmakers of a similar size is 12.5×.

Price to book ratio over time

median 5.8×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	7.5×	6.2×	7.8×
2025	6.3×	4.6×	6.4×
2024	5.0×	5.0×	5.7×
2023	5.3×	5.0×	6.4×
2022	6.2×	5.5×	6.5×
2021	6.4×	6.0×	6.9×
2020	6.4×	5.3×	6.9×
2019	6.6×	5.3×	6.6×
2018	5.3×	4.7×	6.1×
2017	5.1×	4.2×	5.3×
2016	4.3×	3.7×	4.7×
2015	4.0×	3.5×	4.2×
2014	3.8×	3.5×	4.0×
2013	3.7×	3.1×	3.9×
2012	3.0×	2.8×	3.3×
2011	2.9×	2.7×	3.2×
2010	3.0×	3.0×	3.6×
2009	3.5×	3.3×	3.7×

Against its peers

Companies in Drug Manufacturers - General nearest Johnson & Johnson's size, closest first, today.

Company	Price to book ratio
JNJJohnson & Johnson	7.5×
ABBVAbbVie	n/m
MRKMerck	8.5×
LLYEli Lilly and	35.4×
AMGNAmgen	20.3×
GILDGilead Sciences	16.4×
PFEPfizer	2.0×
BMYBristol-Myers Squibb	5.6×
Peer median	12.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Johnson & Johnson

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.